{"id":"vc005","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, VC005 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"VC005 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:16.411Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07329101","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2025-11-11","conditions":"Atopic Dermatitis (AD)","enrollment":10},{"nctId":"NCT07172347","phase":"PHASE2","title":"Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo","status":"RECRUITING","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2025-10-31","conditions":"Non-segmental Vitiligo","enrollment":120},{"nctId":"NCT07172360","phase":"PHASE3","title":"Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.","status":"RECRUITING","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2025-12-26","conditions":"Active Ankylosing Spondylitis","enrollment":420},{"nctId":"NCT06974292","phase":"PHASE1","title":"The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2025-05-26","conditions":"Atopic Dermatitis","enrollment":6},{"nctId":"NCT06891040","phase":"PHASE2","title":"Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2025-04-28","conditions":"Atopic Dermatitis","enrollment":114},{"nctId":"NCT06723080","phase":"PHASE3","title":"Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2024-12-30","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":480},{"nctId":"NCT06009094","phase":"PHASE1","title":"Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2023-07-27","conditions":"Atopic Dermatitis","enrollment":80},{"nctId":"NCT05814939","phase":"PHASE2","title":"Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2023-04-26","conditions":"Active Ankylosing Spondylitis","enrollment":180},{"nctId":"NCT05997927","phase":"PHASE2","title":"Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2023-07-20","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":149},{"nctId":"NCT05874622","phase":"PHASE1","title":"A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2023-06-12","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT05354752","phase":"PHASE1","title":"Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2022-06-18","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT05138770","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics Clinical Study of VC005 Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2021-11-18","conditions":"Inflammatory Bowel Diseases","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VC005","genericName":"VC005","companyName":"Jiangsu vcare pharmaceutical technology co., LTD","companyId":"jiangsu-vcare-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VC005 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}